首页> 外文OA文献 >Expression of receptor activator of nuclear factor κβ ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables

【2h】

Expression of receptor activator of nuclear factor κβ ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables

机译：乳腺癌中核因子κβ配体（RANKL）和肿瘤坏死因子受体激活剂的表达，细胞凋亡诱导配体（TRAIL）的表达及其与骨保护素，雌激素受体的关系以及临床病理变量

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Cross, S S; Harrison, R F; Balasubramanian, S P; Lippitt, J M; Evans, C A; Reed, M W R; Holen, I;
展开▼
作者单位

展开▼
年度 2006
总页数
原文格式 PDF
正文语种 en
中图分类

相似文献

外文文献
中文文献
专利

1. Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological [J] . Cross SS, Harrison RF, Balasubramanian SP, Journal of Clinical Pathology . 2006,第7期

机译：乳腺癌中核因子κ配体（RANKL）和肿瘤坏死因子受体激活剂的表达，细胞凋亡诱导配体（TRAIL）的表达及其与骨保护素，雌激素受体和临床病理的关系
2. Infantile haemangioma expresses tumour necrosis factor-related apoptosis-inducing ligand (TRAIL), TRAIL receptors, osteoprotegerin and receptor activator for nuclear factor small ka, CyrillicB ligand (RANKL). [J] . Vishvanath A, Itinteang T, Tan ST, Histopathology: Official Journal of the British Division of the International Academy of Pathology . 2011,第3期

机译：婴儿血管瘤表达肿瘤坏死因子相关的凋亡诱导配体（TRAIL），TRAIL受体，骨保护素和核因子小ka受体活化剂CyrillicB配体（RANKL）。
3. Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor kappaB ligand (RANKL) in human breast tumours. [J] . Van Poznak C, Cross SS, Saggese M, Journal of Clinical Pathology . 2006,第1期

机译：骨保护素（OPG），TNF相关凋亡诱导配体（TRAIL）和核因子kappaB配体（RANKL）受体激活剂在人乳腺肿瘤中的表达。
4. Effect of Molecular Size of PEGylated tumor necrosis factor factor-related apoptosis apoptosis-inducing ligand(TRAIL) : T The Biological Activity and he Stability [C] . Tae Hyung Kim, Su Young Chae, Seung Min Byun, Annual meeting exposition of the Controlled Release Society . 2009

机译：PEG化肿瘤坏死因子相关细胞凋亡诱导配体（TRAIL）分子大小的影响生物学活性和稳定性
5. Modulation of tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors in a human osteoclast model in vitro. [D] . McManus, Stephen. 2011

机译：在人类破骨细胞模型中调节肿瘤坏死因子相关的凋亡诱导配体（TRAIL）受体。
6. Expression of receptor activator of nuclear factor κβ ligand (RANKL) and tumour necrosis factor related apoptosis inducing ligand (TRAIL) in breast cancer and their relations with osteoprotegerin oestrogen receptor and clinicopathological variables [O] . S S Cross, R F Harrison, S P Balasubramanian, 2006

机译：乳腺癌中核因子κβ配体（RANKL）和肿瘤坏死因子受体激活剂的表达细胞凋亡诱导配体（TRAIL）的表达及其与骨保护素雌激素受体的关系以及临床病理变量
7. Expression of osteoprotegerin (OPG), TNF related apoptosis inducing ligand (TRAIL), and receptor activator of nuclear factor κB ligand (RANKL) in human breast tumours [O] . Van Poznak, C, Cross, S S, Saggese, M, 2006

机译：骨保护素（OPG），TNF相关凋亡诱导配体（TRAIL）和核因子κB配体受体激活剂（RANKL）在人乳腺肿瘤中的表达

Expression of receptor activator of nuclear factor κβ ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables

著录项

相似文献

相关主题

期刊订阅